Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
ApexOnco Front Page
Recent articles
Chengdu Kanghong's KH815 enters human testing this month.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
Vobra-duo is discontinued at long last.
